Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJohnson Matthey Regulatory News (JMAT)

Share Price Information for Johnson Matthey (JMAT)

Share Price is delayed by 15 minutes
Get Live Data
2,080.00    -62.00 (-2.89%)
Bid:
2,066.00
Ask:
2,070.00
Spread: 4.00 (0.194%)
Market Cap: £3.48b
JMAT Live PriceLast checked at - London Stock Exchange

Intraday Johnson Matthey Share Chart

Organisation Changes

20 Apr 2017 16:00

RNS Number : 9050C
Johnson Matthey PLC
20 April 2017
 

For release at 4.00 pm Thursday 20th April 2017

 

JM at 200 - Aligned for Growth

 

Johnson Matthey announces changes to its organisation

 

In 2017 Johnson Matthey celebrates its 200th year and in May we will launch a refreshed brand identity, "Inspiring science, enhancing life", to reflect our position as first and foremost a science led company which has a major positive impact on people's lives; making the world around us cleaner and healthier.

 

Johnson Matthey has made, and continues to make, significant progress in these areas but in order to perform in the current environment, we must increase our focus and build a more collaborative organisation. This will drive further synergies for customers and create value for shareholders. To achieve this, and to reinforce Johnson Matthey's brand identity, we will move to a group structure of four sectors aligned on the global priorities of cleaner air, the efficient use of natural resources and improved health:

· Clean Air

· Efficient Natural Resources

· Health

· New Markets

 

Clean Air is the new name for Emission Control Technologies Division. John Walker, Executive Director, will continue to lead this sector.

 

Efficient Natural Resources brings together Process Technologies Division and much of Precious Metal Products Division. There is an opportunity to deepen our presence in the chemicals, oil and gas, and industrial markets by enabling our customers to increase their efficient use of resources; making more out of less. Jane Toogood, currently Division Director of Precious Metal Products, will lead this sector.

 

Health will comprise much of our Fine Chemicals Division. Johnson Matthey is well positioned to build in this space through focusing on niche areas where we can differentiate using our expertise in complex chemistry. We will bring in a new leader from outside Johnson Matthey to head this sector. In the interim, Robert MacLeod, Chief Executive, will oversee this sector.

 

New Markets is the new name for our New Businesses Division. In addition to the current portfolio of businesses, it will incorporate the Medical Components business previously included in Precious Metal Products' Noble Metals business, and Fine Chemicals' Catalysis and Chiral Technologies business. Alan Nelson, currently Chief Technology Officer and Division Director of New Businesses, will lead this sector.

 

These changes are with immediate effect.

 

 

Enquiries:

Investor Relations

Simon McGough

Sarah Armstrong

 

Head of Investor Relations

Head of Investor Relations

 

020 7269 8235

020 7269 8426

Katharine Burrow

 

Media

Sally Jones

David Allchurch

Investor Relations Analyst

 

 

Director of Corporate Relations

Tulchan Communications

020 7269 8444

 

 

020 7269 8407

020 7353 4200

www.matthey.com

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEALLEALSXEFF
Date   Source Headline
29th Sep 20204:52 pmRNSDirector/PDMR Shareholding
21st Sep 20204:08 pmRNSDirector/PDMR Shareholding
18th Sep 20204:21 pmRNSDirector/PDMR Shareholding
18th Sep 20207:00 amRNSJohnson Matthey: Hydrogen Seminar
21st Aug 20209:05 amRNSDirector/PDMR Shareholding
11th Aug 202010:12 amRNSDoug Webb - New Directorship
6th Aug 20204:19 pmRNSDirector/PDMR Shareholding
6th Aug 20204:11 pmRNSDirector/PDMR Shareholding
5th Aug 20204:25 pmRNSDirector/PDMR Shareholding
5th Aug 20204:21 pmRNSDirector/PDMR Shareholding
5th Aug 20204:04 pmRNSDirector/PDMR Shareholding
30th Jul 20202:45 pmRNSDirector Declaration
23rd Jul 20203:25 pmRNSResult of AGM
23rd Jul 20207:00 amRNSJohnson Matthey Q1 AGM trading update
17th Jul 20201:31 pmRNSDirector/PDMR Shareholding
14th Jul 202012:18 pmRNSDirector/PDMR Shareholding
25th Jun 20207:00 amRNSAnna Manz, CFO, to leave JM and join LSEG
23rd Jun 20207:00 amRNSAnnual Financial Report
19th Jun 20203:14 pmRNSDirector/PDMR Shareholding
16th Jun 20205:13 pmRNSDirector/PDMR Shareholding
16th Jun 20209:00 amRNSCompany Secretary Change
11th Jun 20207:00 amRNSPreliminary results for year ended 31st March 2020
4th Jun 20204:35 pmRNSDirector/PDMR Shareholding
21st May 20204:08 pmRNSDirector/PDMR Shareholding
12th May 20207:00 amRNSJohnson Matthey revised date for full year results
28th Apr 20203:45 pmRNSRights attaching to ordinary shares
22nd Apr 20207:00 amRNSJM and COVID-19: supporting our stakeholders
16th Apr 20204:56 pmRNSDirector/PDMR Shareholding
2nd Apr 202010:31 amRNSJane Griffiths - New Directorship
1st Apr 20207:00 amRNSCompany Secretary Change
30th Mar 20207:00 amRNSJohnson Matthey pre-close trading statement
19th Mar 20203:11 pmRNSDirector/PDMR Shareholding
25th Feb 202011:04 amRNSDirector/PDMR Shareholding
20th Feb 20203:35 pmRNSDirector/PDMR Shareholding
6th Feb 20205:33 pmRNSDirector/PDMR Shareholding
6th Feb 20203:52 pmRNSDirector/PDMR Shareholding
6th Feb 20203:41 pmRNSDirector/PDMR Shareholding
6th Feb 20203:29 pmRNSDirector/PDMR Shareholding
4th Feb 20207:30 amRNSJohn O'Higgins - New Directorship
17th Jan 202010:09 amRNSDirector/PDMR Shareholding
19th Dec 20194:31 pmRNSDirector/PDMR Shareholding
26th Nov 20195:06 pmRNSHolding(s) in Company
26th Nov 20195:01 pmRNSDirector/PDMR Shareholding
26th Nov 20194:53 pmRNSDirector/PDMR Shareholding
26th Nov 20194:41 pmRNSDirector/PDMR Shareholding
25th Nov 201911:56 amRNSDirector/PDMR Shareholding
25th Nov 201910:18 amRNSDirector/PDMR Shareholding
21st Nov 20192:24 pmRNSDirector/PDMR Shareholding
21st Nov 20197:00 amRNSHalf-year Report
17th Oct 20193:46 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.